Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assurance.
Fiche publication
Date publication
février 2024
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PRETET Jean-Luc
Tous les auteurs :
Prétet JL, Arroyo Mühr LS, Cuschieri K, Fellner MD, Correa RM, Picconi MA, Garland SM, Murray GL, Molano M, Peeters M, Van Gucht S, Lambrecht C, Broeck DV, Padalko E, Arbyn M, Lepiller Q, Brunier A, Silling S, Søreng K, Christiansen IK, Poljak M, Lagheden C, Yilmaz E, Eklund C, Thapa HR, Querec TD, Unger ER, Dillner J
Lien Pubmed
Résumé
Some high-grade cervical lesions and cervical cancers (HSIL+) test negative for human papillomavirus (HPV). The HPV-negative fraction varies between 0.03 % and 15 % between different laboratories. Monitoring and extended re-analysis of HPV-negative HSIL+ could thus be helpful to monitor performance of HPV testing services. We aimed to a) provide a real-life example of a quality assurance (QA) program based on re-analysis of HPV-negative HSIL+ and b) develop international guidance for QA of HPV testing services based on standardized identification of apparently HPV-negative HSIL+ and extended re-analysis, either by the primary laboratory or by a national HPV reference laboratory (NRL).
Mots clés
Cervical cancer, HPV testing, HSIL, Human papillomavirus, Quality assurance, Screening
Référence
J Clin Virol. 2024 02 20;171:105657